• Front Matter R1-R20

• Executive Summary 1-25

• 1 Introduction 26-42

• 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction 43-73

• 3 Assessment of the Medications Development Division 74-94

• 4 Treatment Setting and Effectiveness 95-119

• 5 Treatment Financing and Trends in Health Insurance 120-133

• 6 Training and Education 134-153

• 7 Federal Laws and Regulations 154-172

• 8 State Laws and Regulations 173-186

• 9 Market Obstacles and Creating Incentives 187-200

• Appendix A: Acknowledgments 201-206

• Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches 207-210

• Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence 211-214

• Appendix D: Survey of Pharmaceutical Companies 215-226

• Appendix E: Model Federal Programs in Pharmaceutical R&D 227-237

• Appendix F: Workshop Agenda and Participants 238-241

• Appendix G: Health Care Reform Legislation 242-247

• Appendix H: Acronyms 248-250

" Appendix F: Workshop Agenda and Participants ." The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector . Washington, DC: The National Academies Press, 1995 .

Please select a format: